This article is more than 5 years old. Information may no longer be current.

VIDEO: Targeted agents, immunotherapies fill unmet needs for hard-to-treat cancers

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Aron Knickerbocker, MBA, CEO of Five Prime Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about advances in the company’s oncology program.

One study presented at ASCO focused on use of cabiralizumab (FPA008, Five Prime Therapeutics) — an antibody that inhibits colony stimulating factor-1 receptor — in combination with the PD-1 immune checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb) for heavily pretreated patients with pancreatic cancer.

“Nearly all of the patients in this study were tumor mutation burden low, and those are not the type of patients who are historically very sensitive to PD-1 inhibition, so that is very interesting,” Knickerbocker told HemOnc Today.

Knickerbocker also spoke about bemarituzumab (FPA144, Five Prime Therapeutics) — an antibody that targets FGF receptor 2, which is overexpressed in approximately 10% of gastric and gastroesophageal cancers — as well as what he described as other “first-in-class immuno-oncology agents” in the company’s pipeline.

“A lot is going over the next 6 to 12 months at Five Prime, and we should end the year with five products in development between us and our partners,” Knickerbocker told HemOnc Today.